Posted by Michael Wonder on 09 Oct 2020
Johnson & Johnson announces European Commission approval of agreement to supply 200 million doses of Janssen’s COVID-19 vaccine candidate
8 October 2020 - Agreement provides option for European Union Member States to secure up to 200 million additional doses for a total of up to 400 million doses.
Johnson & Johnson today announced the European Commission, acting on behalf of the European Union (EU) Member States, has approved an Advance Purchase Agreement in which the Janssen Pharmaceutical Companies will supply 200 million doses of its COVID-19 vaccine candidate to EU Member States following approval or authorisation from regulators.
The EU Member States also have the option to secure up to 200 million additional doses.
